RC48 (disitamab vedotin)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for RC48 (disitamab vedotin), covering 2024-12-04 to 2026-01-26. Get the full timeline:
Most recent: Clinical Trial Update: RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure [Phase 2, Phase 3]